Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,394 result(s) found. Displaying page 1,845 of 2,220.
    «« First « Previous 1841  1842  1843  1844  1845  1846  1847  1848  1849  Next» Last»»
    EudraCT Number: 2019-003819-56 Sponsor Protocol Number: 26193789 Start Date*: 2020-06-12
    Sponsor Name:Centre for Surgical Science
    Full Title: Effects of intravenous administered iron in non-anemic iron deficient patients with colorectal cancer. A double blinded clinical randomized trial.
    Medical condition: Iron-deficiency in colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009944 Colon cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038038 Rectal cancer PT
    20.0 10027433 - Metabolism and nutrition disorders 10022970 Iron deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-004142-35 Sponsor Protocol Number: ABSALON Start Date*: 2023-04-18
    Sponsor Name:Department of Ophthalmology, Rigshospitalet
    Full Title: Additive Benefits of Semaglutide for open-AngLe glaucoma – an Opportunity for Neuroprotection (ABSALON)
    Medical condition: mild and moderate glaucoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10036719 Primary open angle glaucoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001785-29 Sponsor Protocol Number: ARIS2 Start Date*: 2016-08-15
    Sponsor Name:St. Vincent's University Hospital
    Full Title: Combined Effect of CFTR Modifiers and Intensive Antibiotic Treatment
    Medical condition: Cystic fibrosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004471-31 Sponsor Protocol Number: I4V-MC-JAHX Start Date*: 2019-06-13
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients from 1 Year to <18 Years of Age with Juvenile Idiopathic Arthritis (JIA)
    Medical condition: Juvenile Idiopathic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) PL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2023-000029-10 Sponsor Protocol Number: DESC-HBR Start Date*: 2023-03-24
    Sponsor Name:Azienda Ospedaliera Universitaria Gaetano Martino Messina
    Full Title: De-Escalation of Antiplatelet Therapy to Evaluate Platelet Reactivity and Clinical Outcomes after Coronary Stenting in Patients at High Bleeding Risk and Recent Acute Coronary Syndrome: DESC-HBR trial
    Medical condition: High bleeding risk (HBR) patients with a recent acute coronary syndrome (ACS ) who have undergone percutaneous coronary intervention (PCI) and are on double antiplatelet therapy (DAPT)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000757-93 Sponsor Protocol Number: ISIS721744-CS7 Start Date*: 2022-09-05
    Sponsor Name:IONIS PHARMACEUTICALS, INC.
    Full Title: An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
    Medical condition: Hereditary Angioedema (HAE)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10010331 - Congenital, familial and genetic disorders 10019860 Hereditary angioedema PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) NL (Ongoing) DK (Completed) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004670-25 Sponsor Protocol Number: CQ-001-19 Start Date*: 2022-11-16
    Sponsor Name:Corequest sagl
    Full Title: Peritoneal Ultrafiltration in cardio Renal syndrome to prevent heart failure Exacerbation: The PURE Study
    Medical condition: Congestive Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    20.1 10007541 - Cardiac disorders 10007559 Cardiac failure congestive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000952-11 Sponsor Protocol Number: PR-30-5017-C Start Date*: 2016-07-01
    Sponsor Name:TESARO, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Base...
    Medical condition: Homologous recombination deficiency advanced ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FI (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) IE (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2022-000880-40 Sponsor Protocol Number: R2477-FOP-2175 Start Date*: 2022-08-29
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability, and Efficacy of Garetosmab in Patients with Fibrodysplasia Ossificans Progressiva
    Medical condition: Fibrodysplasia Ossificans Progressiva
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10068715 Fibrodysplasia ossificans progressiva PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) FI (Trial now transitioned) IT (Trial now transitioned) NL (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-004122-22 Sponsor Protocol Number: APHP220097 Start Date*: 2023-06-02
    Sponsor Name:ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP)
    Full Title: Monalizumab and MEDI5752 in patients with MSI and/or dMMR metastatic cancer
    Medical condition: adult patients in all MSI/DMMR solid tumor types
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006229-23 Sponsor Protocol Number: PTCLS-IDE Start Date*: 2022-04-07
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T-cell Lymphomas.
    Medical condition: peripheral T Cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10003622 ATLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005608-20 Sponsor Protocol Number: D1346C00004 Start Date*: 2021-11-24
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase I/II, Single-Arm, Open label Study to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥ 1 to < 7 Years with Neurofibr...
    Medical condition: Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10029270 Neurofibromatosis, type 1 (von Recklinghausen's disease) LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) NL (Prematurely Ended) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002443-21 Sponsor Protocol Number: CO44195 Start Date*: 2023-03-01
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: A PHASE II, SINGLE-ARM STUDY OF GIREDESTRANT IN PATIENTS WITH GRADE 1 ENDOMETRIAL CANCER
    Medical condition: Grade 1 Endometrial Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014738 Endometrial cancer stage I PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001759-17 Sponsor Protocol Number: FGTW2101 Start Date*: 2022-10-04
    Sponsor Name:Laboratoire français du Fractionnement et des Biotechnologies (LFB BIOTECHNOLOGIES)
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel, phase 3 study to assess the efficacy and safety of fibrinogen concentrate (FGTW) in the management of bleeding in patients und...
    Medical condition: Bleeding in patients undergoing complex cardiac surgery (involving CPB)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022117 - Injury, poisoning and procedural complications 10017501 Functional disturbances following cardiac surgery LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003286-34 Sponsor Protocol Number: CHUBX2017/22 Start Date*: 2019-03-05
    Sponsor Name:CHU de Bordeaux
    Full Title: In vivo involvement of the cholinergic and dopaminergic systems in the pathophysiology of apathy.
    Medical condition: Apathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10002942 Apathy PT
    20.0 100000004852 10042244 Stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000058-89 Sponsor Protocol Number: D516AC00001 Start Date*: 2021-01-06
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomised, Controlled, Multi-center, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treat...
    Medical condition: Patients with histologically or cytologically documented non-squamous NSCLC with completely resectable (Stage II - IIIB N2) disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029518 Non-small cell lung cancer stage II PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) AT (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004225-22 Sponsor Protocol Number: CSEG101A2401B Start Date*: 2021-05-03
    Sponsor Name:Novartis Pharma AG
    Full Title: An Open-label, Multi-center, Phase IV, Rollover Study for Patients with Sickle Cell Disease who have Completed a Prior Novartis-Sponsored Crizanlizumab Study
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    20.1 10010331 - Congenital, familial and genetic disorders 10002077 Anaemia sickle cell LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003079-16 Sponsor Protocol Number: INS-416 Start Date*: 2021-02-08
    Sponsor Name:Insmed Incorporated
    Full Title: ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen ...
    Medical condition: Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)
    Disease: Version SOC Term Classification Code Term Level
    22.1 10021881 - Infections and infestations 10061229 Lung infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) FR (Trial now transitioned) DE (Ongoing) AT (Trial now transitioned) HU (Completed) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000949-14 Sponsor Protocol Number: VIB0551.P3.S1 Start Date*: 2020-11-16
    Sponsor Name:Viela Bio, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 3 STUDY WITH OPEN-LABEL PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF INEBILIZUMAB IN ADULTS WITH MYASTHENIA GRAVIS
    Medical condition: Myasthenia Gravis which is either due to acetylcholine receptor antibodies (AChR) or muscle specific kinase antibodies (MuSK).
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DK (Prematurely Ended) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001979-36 Sponsor Protocol Number: J2G-MC-JZJC Start Date*: 2020-07-14
    Sponsor Name:Eli Lilly and Company
    Full Title: LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab as Initial Treatment of Advanced or...
    Medical condition: Male or female patients with advanced, treatment-naïve RET Fusion-Positive Non-Squamous NSCLC
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) CZ (Completed) GR (Trial now transitioned) FR (Trial now transitioned) PL (Completed) NL (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Trial now transitioned) IT (Trial now transitioned) RO (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1841  1842  1843  1844  1845  1846  1847  1848  1849  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 28 19:09:26 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA